Daniel Strbian1, Peter Ringleb, Patrik Michel, Lorenz Breuer, Jyrki Ollikainen, Kei Murao, David J Seiffge, Simon Jung, Victor Obach, Bruno Weder, Ashraf Eskandari, Henrik Gensicke, Angel Chamorro, Heinrich P Mattle, Stefan Engelter, Didier Leys, Heikki Numminen, Martin Köhrmann, Werner Hacke, Turgut Tatlisumak. 1. From the Departments of Neurology and Stroke Units, Helsinki University Central Hospital, Helsinki, Finland (D.S., T.T.); Department of Neurology, University of Heidelberg, Heidelberg, Germany (P.R., W.H.); Department of Neurology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland (P.M., A.E.); Department of Neurology, Universitätsklinikum Erlangen, Erlangen, Germany (L.B., M.K.); Department of Neurology, Tampere University Hospital, Tampere, Finland (J.O., H.N.); Department of Neurology, University Lille Nord de France (K.M., D.L.); Department of Neurology and Stroke Units, University Hospital Basel, Basel, Switzerland (D.J.S., H.G., S.E.); Department of Neurology, University of Bern, Bern, Switzerland (S.J., B.W., H.P.M.); Department of Neurology, Hospital Clínic Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain (V.O., A.C.); and Department of Neurology, Kantonsspital St. Gallen, St. Gallen, Switzerland (B.W.).
Abstract
BACKGROUND AND PURPOSE: We previously reported increased benefit and reduced mortality after ultra-early stroke thrombolysis in a single center. We now explored in a large multicenter cohort whether extra benefit of treatment within 90 minutes from symptom onset is uniform across predefined stroke severity subgroups, as compared with later thrombolysis. METHODS: Prospectively collected data of consecutive ischemic stroke patients who received i.v. thrombolysis in 10 European stroke centers were merged. Logistic regression tested association between treatment delays, as well as excellent 3-month outcome (modified Rankin scale, 0-1), and mortality. The association was tested separately in tertiles of baseline National Institutes of Health Stroke Scale. RESULTS: In the whole cohort (n=6856), shorter onset-to-treatment time as a continuous variable was significantly associated with excellent outcome (P<0.001). Every fifth patient had onset-to-treatment time≤90 minutes, and these patients had lower frequency of intracranial hemorrhage. After adjusting for age, sex, admission glucose level, and year of treatment, onset-to-treatment time≤90 minutes was associated with excellent outcome in patients with National Institutes of Health Stroke Scale 7 to 12 (odds ratio, 1.37; 95% confidence interval, 1.11-1.70; P=0.004), but not in patients with baseline National Institutes of Health Stroke Scale>12 (odds ratio, 1.00; 95% confidence interval, 0.76-1.32; P=0.99) and baseline National Institutes of Health Stroke Scale 0 to 6 (odds ratio, 1.04; 95% confidence interval, 0.78-1.39; P=0.80). In the latter, however, an independent association (odds ratio, 1.51; 95% confidence interval, 1.14-2.01; P<0.01) was found when considering modified Rankin scale 0 as outcome (to overcome the possible ceiling effect from spontaneous better prognosis of patients with mild symptoms). Ultra-early treatment was not associated with mortality. CONCLUSIONS: I.v. thrombolysis within 90 minutes is, compared with later thrombolysis, strongly and independently associated with excellent outcome in patients with moderate and mild stroke severity.
BACKGROUND AND PURPOSE: We previously reported increased benefit and reduced mortality after ultra-early stroke thrombolysis in a single center. We now explored in a large multicenter cohort whether extra benefit of treatment within 90 minutes from symptom onset is uniform across predefined stroke severity subgroups, as compared with later thrombolysis. METHODS: Prospectively collected data of consecutive ischemic strokepatients who received i.v. thrombolysis in 10 European stroke centers were merged. Logistic regression tested association between treatment delays, as well as excellent 3-month outcome (modified Rankin scale, 0-1), and mortality. The association was tested separately in tertiles of baseline National Institutes of Health Stroke Scale. RESULTS: In the whole cohort (n=6856), shorter onset-to-treatment time as a continuous variable was significantly associated with excellent outcome (P<0.001). Every fifth patient had onset-to-treatment time≤90 minutes, and these patients had lower frequency of intracranial hemorrhage. After adjusting for age, sex, admission glucose level, and year of treatment, onset-to-treatment time≤90 minutes was associated with excellent outcome in patients with National Institutes of Health Stroke Scale 7 to 12 (odds ratio, 1.37; 95% confidence interval, 1.11-1.70; P=0.004), but not in patients with baseline National Institutes of Health Stroke Scale>12 (odds ratio, 1.00; 95% confidence interval, 0.76-1.32; P=0.99) and baseline National Institutes of Health Stroke Scale 0 to 6 (odds ratio, 1.04; 95% confidence interval, 0.78-1.39; P=0.80). In the latter, however, an independent association (odds ratio, 1.51; 95% confidence interval, 1.14-2.01; P<0.01) was found when considering modified Rankin scale 0 as outcome (to overcome the possible ceiling effect from spontaneous better prognosis of patients with mild symptoms). Ultra-early treatment was not associated with mortality. CONCLUSIONS: I.v. thrombolysis within 90 minutes is, compared with later thrombolysis, strongly and independently associated with excellent outcome in patients with moderate and mild stroke severity.
Entities:
Keywords:
emergencies; ischemic stroke; onset to needle time; outcome; thrombolysis
Authors: Elisabeth Breese Marsh; Richard Leigh; Martin Radvany; Philippe Gailloud; Rafael H Llinas Journal: Front Neurol Date: 2014-10-14 Impact factor: 4.003
Authors: Robert Abtan; Nooshin Khobzi Rotondi; Alison Macpherson; Michael Anthony Rotondi Journal: BMC Health Serv Res Date: 2018-01-31 Impact factor: 2.655
Authors: Jan F Scheitz; Henrik Gensicke; Sanne M Zinkstok; Sami Curtze; Marcel Arnold; Christian Hametner; Alessandro Pezzini; Guillaume Turc; Andrea Zini; Visnja Padjen; Susanne Wegener; Annika Nordanstig; Lars Kellert; Georg Kägi; Yannick Bejot; Patrik Michel; Didier Leys; Christian H Nolte; Paul J Nederkoorn; Stefan T Engelter Journal: BMJ Open Date: 2018-09-17 Impact factor: 2.692